Microfluidic Blood-Brain Barrier Device for Drug Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current in vitro and in vivo assays for drug delivery across the blood-brain barrier lack cost-effectiveness and high-throughput capabilities for real-time visualization and quantitation, failing to accurately reproduce physiological microenvironmental parameters and shear stress.
Innovation Solution
The Synthetic Microvascular Blood-Brain Barrier (SyM-BBB) device, utilizing polydimethylsiloxane microfluidic chips with embedded microfluidic flow channels and porous walls, recreates in vivo conditions for drug and drug carrier transport studies, enabling real-time visualization and quantitation of drug penetration across the BBB.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If static well-plate incubation assays are used, then the device complexity is reduced, but the physiological relevance and measurement precision deteriorate
Solution Approach 1:
The patent creates a microfluidic copy of the in vivo blood-brain barrier environment, replicating physiological microenvironmental parameters, shear stress, and transport effects in a simplified chip format that maintains measurement precision while reducing device complexity
Solution Approach 2:
The patent changes physical parameters by introducing controlled fluid flow to generate physiological shear stress and by scaling down dimensions to microfluidic scales, thereby improving physiological relevance without significantly increasing device complexity
2Measurement precision
If in vivo BBB assays using small animal models are used, then the measurement precision is improved, but the productivity and loss of time worsen
Solution Approach 1:
The patent employs disposable microfluidic chips that can be rapidly prepared and discarded, eliminating the need for expensive, time-consuming animal models while maintaining measurement precision and enabling high-throughput screening
Solution Approach 2:
The patent segments the complex in vivo system into isolated microfluidic chambers that replicate specific BBB functions, allowing parallel processing and high-throughput screening without the constraints of whole animal models
3Measurement precision
If in vivo BBB assays using small animal models are used, then the measurement precision is improved, but the loss of time worsens
Solution Approach 1:
The patent performs preliminary actions by pre-coating microfluidic channels with extracellular matrix and pre-seeding cells in controlled environments, allowing assays to begin immediately with physiological conditions already established, thereby reducing assay time while maintaining precision
4Device complexity
If available in vitro BBB assays using filter membranes are used, then the device complexity is reduced, but the physiological relevance deteriorates
Solution Approach 1:
The patent applies hydraulic principles by introducing controlled fluid flow through microchannels to generate physiological shear stress on endothelial cells, thereby improving physiological relevance while maintaining relatively simple device architecture
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a cost-effective, high-throughput method for accurately assessing drug delivery across the BBB, allowing for the study of normal and pathological conditions, and enabling the screening of therapeutics for CNS applications.
Implementation Method 1
The walls separating the flow channels from the tissue spaces comprise gaps with dimensions between 0.2 μm to 5 μm such that liquid may diffuse from the flow channels into the tissue spaces
Data Source
AI summary
An apparatus and method for assaying blood-brain barrier properties for drug and drug delivery vehicle screening comprising of a microfluidic apparatus with gaps separating lumen and tissue space enabling formation of tight junctions similar to in vivo conditions using endothelial cells and brain cells.